Theravance Biopharma, Inc. (TBPH) Position Cut by Morgan Stanley

Morgan Stanley cut its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 45.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,118 shares of the biopharmaceutical company’s stock after selling 55,404 shares during the period. Morgan Stanley owned approximately 0.13% of Theravance Biopharma worth $2,471,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the stock. American International Group Inc. increased its stake in shares of Theravance Biopharma by 16.4% in the first quarter. American International Group Inc. now owns 24,276 shares of the biopharmaceutical company’s stock valued at $894,000 after buying an additional 3,417 shares during the last quarter. Harvest Management LLC purchased a new stake in shares of Theravance Biopharma during the first quarter valued at approximately $228,000. Parametric Portfolio Associates LLC increased its stake in shares of Theravance Biopharma by 3.3% in the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock valued at $519,000 after buying an additional 456 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Theravance Biopharma by 5.8% in the first quarter. Geode Capital Management LLC now owns 330,280 shares of the biopharmaceutical company’s stock valued at $12,160,000 after buying an additional 18,177 shares during the last quarter. Finally, American Century Companies Inc. purchased a new stake in shares of Theravance Biopharma during the first quarter valued at approximately $1,132,000. 82.77% of the stock is owned by hedge funds and other institutional investors.

Shares of Theravance Biopharma, Inc. (TBPH) traded up 0.59% during midday trading on Friday, hitting $28.80. 35,033 shares of the stock traded hands. Theravance Biopharma, Inc. has a 52 week low of $23.15 and a 52 week high of $43.44. The stock’s market capitalization is $1.55 billion. The firm has a 50-day moving average price of $32.61 and a 200-day moving average price of $35.28.

TRADEMARK VIOLATION NOTICE: “[[title]]” was first reported by [[site]] and is the sole property of of [[site]]. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at [[permalink]].

Several equities research analysts have recently issued reports on TBPH shares. Needham & Company LLC increased their price objective on shares of Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. BidaskClub downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Finally, Leerink Swann set a $47.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $41.63.

In other Theravance Biopharma news, Director Henrietta Fore acquired 6,000 shares of Theravance Biopharma stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $23.99 per share, for a total transaction of $143,940.00. Following the acquisition, the director now owns 24,000 shares of the company’s stock, valued at $575,760. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Frank Pasqualone acquired 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average price of $26.34 per share, with a total value of $105,360.00. Following the completion of the acquisition, the senior vice president now directly owns 213,180 shares in the company, valued at approximately $5,615,161.20. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 20,000 shares of company stock valued at $494,300. 6.10% of the stock is owned by insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).